CRLBF stock forecast for June suggests potential volatility tied to macroeconomic indicators, with interest rate cuts possibly improving investor risk appetite toward growth stocks like cannabis. Compared to the Zacks Consensus Estimate of $181.36 million, the reported revenues represent a surprise of +3.8%. The EPS surprise was +150%. Cresco Labs (OTCMKTS: CRLBF ) and its affiliated companies cultivates, manufactures and sells retail and medical cannabis products in the U.S. Cannabis stocks were all the rage in 2018 and 2019. But the bubble quickly burst. It became apparent the U.S. wasn’t going to reclassify marijuana as a Schedule 1 drug. Analysts tracking CRLBF stock forecast cite that sector rotation into cannabis-related equities may lift valuations, especially with favorable state-level revenue data emerging in recent reports.